149 related articles for article (PubMed ID: 38440132)
1. Tacrolimus Drug Exposure Level and Smoking Are Modifiable Risk Factors for Early
Vanlerberghe BTK; van Malenstein H; Sainz-Barriga M; Jochmans I; Cassiman D; Monbaliu D; van der Merwe S; Pirenne J; Nevens F; Verbeek J
Transpl Int; 2024; 37():12055. PubMed ID: 38440132
[No Abstract] [Full Text] [Related]
2. Cumulative exposure to tacrolimus and incidence of cancer after liver transplantation.
Rodríguez-Perálvarez M; Colmenero J; González A; Gastaca M; Curell A; Caballero-Marcos A; Sánchez-Martínez A; Di Maira T; Herrero JI; Almohalla C; Lorente S; Cuadrado-Lavín A; Pascual S; López-Garrido MÁ; González-Grande R; Gómez-Orellana A; Alejandre R; Zamora-Olaya J; Bernal-Bellido C;
Am J Transplant; 2022 Jun; 22(6):1671-1682. PubMed ID: 35286761
[TBL] [Abstract][Full Text] [Related]
3. Minimizing tacrolimus decreases the risk of new-onset diabetes mellitus after liver transplantation.
Song JL; Gao W; Zhong Y; Yan LN; Yang JY; Wen TF; Li B; Wang WT; Wu H; Xu MQ; Chen ZY; Wei YG; Jiang L; Yang J
World J Gastroenterol; 2016 Feb; 22(6):2133-41. PubMed ID: 26877618
[TBL] [Abstract][Full Text] [Related]
4. Tacrolimus exposure after liver transplantation for alcohol-related liver disease: Impact on complications.
Bardou FN; Guillaud O; Erard-Poinsot D; Chambon-Augoyard C; Thimonier E; Vallin M; Boillot O; Dumortier J
Transpl Immunol; 2019 Oct; 56():101227. PubMed ID: 31351125
[TBL] [Abstract][Full Text] [Related]
5. The 28-year incidence of de novo malignancies after liver transplantation: A single-center analysis of risk factors and mortality in 1616 patients.
Rademacher S; Seehofer D; Eurich D; Schoening W; Neuhaus R; Oellinger R; Denecke T; Pascher A; Schott E; Sinn M; Neuhaus P; Pratschke J
Liver Transpl; 2017 Nov; 23(11):1404-1414. PubMed ID: 28590598
[TBL] [Abstract][Full Text] [Related]
6. Area Under Trough Concentrations of Tacrolimus as a Predictor of Progressive Renal Impairment After Liver Transplantation.
Rodríguez-Perálvarez M; Guerrero M; De Luca L; Gros B; Thorburn D; Patch D; Aumente MD; Westbrook R; Fernández R; Amado V; Aguilar P; Montero JL; O'Beirne J; Briceño J; Tsochatzis E; De la Mata M
Transplantation; 2019 Dec; 103(12):2539-2548. PubMed ID: 31107827
[TBL] [Abstract][Full Text] [Related]
7. De Novo Malignancy After Adult-to-Adult Living Donor Liver Transplantation: A Single-Center Long-Term Experience.
Masuda Y; Mita A; Ohno Y; Kubota K; Notake T; Shimizu A; Soejima Y
Transplant Proc; 2023 May; 55(4):952-955. PubMed ID: 37088616
[TBL] [Abstract][Full Text] [Related]
8. Malignancy After Living Donor Liver Transplantation.
Kobayashi T; Miura K; Ishikawa H; Sakata J; Takizawa K; Hirose Y; Toge K; Saito S; Abe S; Kawachi Y; Ichikawa H; Shimada Y; Takahashi Y; Wakai T; Kinoshita Y
Transplant Proc; 2024 Apr; 56(3):660-666. PubMed ID: 38519268
[TBL] [Abstract][Full Text] [Related]
9. Hepatocellular carcinoma and the risk of de novo malignancies after liver transplantation - a multicenter cohort study.
Shalaby S; Taborelli M; Zanetto A; Ferrarese A; D'Arcangelo F; Gambato M; Senzolo M; Russo FP; Germani G; Boccagni P; Ettorre GM; Baccarani U; Lauro A; Galatioto L; Rendina M; Petrara R; De Rossi A; Nudo F; Toti L; Fantola G; Vennarecci G; Risaliti A; Pinna AD; Gruttadauria S; Di Leo A; Rossi M; Tisone G; Zamboni F; Cillo U; Piselli P; Serraino D; Burra P;
Transpl Int; 2021 Apr; 34(4):743-753. PubMed ID: 33492715
[TBL] [Abstract][Full Text] [Related]
10. Gender, Race and Disease Etiology Predict De Novo Malignancy Risk After Liver Transplantation: Insights for Future Individualized Cancer Screening Guidance.
Bhat M; Mara K; Dierkhising R; Watt KD
Transplantation; 2019 Jan; 103(1):91-100. PubMed ID: 29377876
[TBL] [Abstract][Full Text] [Related]
11. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence.
Vivarelli M; Cucchetti A; La Barba G; Ravaioli M; Del Gaudio M; Lauro A; Grazi GL; Pinna AD
Ann Surg; 2008 Nov; 248(5):857-62. PubMed ID: 18948815
[TBL] [Abstract][Full Text] [Related]
12. Reduced calcineurin inhibitor exposure with antibody induction and recurrent hepatocellular carcinoma after liver transplantation.
Abrahamsson J; Sternby Eilard M; Rizell M; Bennett W; Åberg F
Scand J Gastroenterol; 2022 Mar; 57(3):325-332. PubMed ID: 34871120
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up after liver transplantation for alcoholic liver disease under tacrolimus.
Jain A; DiMartini A; Kashyap R; Youk A; Rohal S; Fung J
Transplantation; 2000 Nov; 70(9):1335-42. PubMed ID: 11087149
[TBL] [Abstract][Full Text] [Related]
14. The impact of long-term exposure to tacrolimus on chronic kidney disease after lung transplantation: A retrospective analysis from a single transplantation center.
Xiong D; Yue B; Ye S; Wang H; Ban L; Chen Y; Lv J; Zhou M; Yin P; Chen J
Transpl Immunol; 2023 Jun; 78():101810. PubMed ID: 36918103
[TBL] [Abstract][Full Text] [Related]
15. Long-term probability of and mortality from de novo malignancy after liver transplantation.
Watt KD; Pedersen RA; Kremers WK; Heimbach JK; Sanchez W; Gores GJ
Gastroenterology; 2009 Dec; 137(6):2010-7. PubMed ID: 19766646
[TBL] [Abstract][Full Text] [Related]
16. Tacrolimus and the risk of solid cancers after liver transplant: a dose effect relationship.
Carenco C; Assenat E; Faure S; Duny Y; Danan G; Bismuth M; Herrero A; Jung B; Ursic-Bedoya J; Jaber S; Larrey D; Navarro F; Pageaux GP
Am J Transplant; 2015 Mar; 15(3):678-86. PubMed ID: 25648361
[TBL] [Abstract][Full Text] [Related]
17. Long-term survival after liver transplantation for alcoholic liver disease.
Iruzubieta P; Crespo J; Fábrega E
World J Gastroenterol; 2013 Dec; 19(48):9198-208. PubMed ID: 24409048
[TBL] [Abstract][Full Text] [Related]
18. Impact of cyclosporine versus tacrolimus on the incidence of de novo malignancy following liver transplantation: a single center experience with 609 patients.
Wimmer CD; Angele MK; Schwarz B; Pratschke S; Rentsch M; Khandoga A; Guba M; Jauch KW; Bruns C; Graeb C
Transpl Int; 2013 Oct; 26(10):999-1006. PubMed ID: 23952102
[TBL] [Abstract][Full Text] [Related]
19. Donor Age Predicts Calcineurin Inhibitor Induced Neurotoxicity After Liver Transplantation.
Lué A; Martinez E; Navarro M; Laredo V; Lorente S; Jose Araiz J; Agustin Garcia-Gil F; Serrano MT
Transplantation; 2019 Aug; 103(8):e211-e215. PubMed ID: 30985573
[TBL] [Abstract][Full Text] [Related]
20. Natural History of Established and De Novo Inflammatory Bowel Disease After Liver Transplantation for Primary Sclerosing Cholangitis.
Mouchli MA; Singh S; Boardman L; Bruining DH; Lightner AL; Rosen CB; Heimbach JK; Hasan B; Poterucha JJ; Watt KD; Kane SV; Raffals LE; Loftus EV
Inflamm Bowel Dis; 2018 Apr; 24(5):1074-1081. PubMed ID: 29522202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
